0
Rocket Pharmaceuticals, Inc. Banner Image

Rocket Pharmaceuticals, Inc. has reached its limit for free report views

Work for Rocket Pharmaceuticals, Inc.? Upgrade Your Profile and unlock all your annual reports.

Rocket Pharmaceuticals, Inc.

  • Ticker RCKT
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Rocket Pharmaceuticals, Inc. Logo Image
  • 51-200 Employees
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”) is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare childhood disorders. The company’s platform-agnostic approach enables it to design the best therapy for each indication, creating potentially transformative options for patients afflicted with rare genetic diseasesMore. Rocket's clinical programs using lentiviral vector (LVV)-based gene therapy are for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, Pyruvate Kinase Deficiency (PKD) a rare, monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia and Infantile Malignant Osteopetrosis (IMO), a bone marrow-derived disorder. Rocket’s first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon disease, a devastating, pediatric heart failure condition.
Rocket Pharmaceuticals, Inc.

Most Recent Annual Report

Rocket Pharmaceuticals, Inc. MOST RECENT 2019 Annual Report and Form 10K

Report Locked. Rocket Pharmaceuticals, Inc. has reached its limit for free report views.

Older/Archived Annual Reports